Skip to main content
SpringerLink
Log in

Polymyalgia Rheumatica and Giant Cell Arteritis in the Elderly

  • Chapter
  • First Online:
Geriatric Rheumatology

  • 1225 Accesses

Abstract

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) occur almost exclusively in persons aged ³50 years. The prevalence in USA is 0.3% for PMR and 0.1% for GCA. GCA occurs in at least 15% of PMR patients. About 40% of GCA patients exhibit symptoms of PMR. PMR is characterized by sudden onset of shoulder and/or pelvic girdle pain with malaise and signs of inflammation. Typical symptoms for GCA are headache, swollen and tender temporal arteries, and jaw claudication. Ophthalmic complications such as anterior ischemic optic neuropathy, amaurosis fugax, or diplopia often occur in untreated disease. Large-vessel GCA particularly involves the proximal arm arteries. Symptoms may be less typical than in classic temporal arteritis. ESR and CRP are highly elevated. Magnetic resonance imaging (MRI) or ultrasound shows glenohumeral synovitis, subdeltoid bursitis, biceps tenosynovitis, hip synovitis, and/or trochanteric bursitis in PMR. Ultrasound and MRI scans ­display inflammatory wall swelling; ultrasound also detects stenoses and occlusions in acutely inflamed temporal arteries. Imaging is also a valuable tool for large-vessel GCA. Temporal artery histology displays mononuclear infiltrates, granulomas, and/or giant cells in acute temporal arteritis. Imaging may replace histology in experienced centers if ­findings are typical. Corticosteroids remain the mainstay of treatment. Starting doses are 15–25 mg/day of prednisone for PMR and 40–70 mg/day for GCA. Dose reduction should be consequent, always trying to reach the lowest effective dose. Methotrexate can be provided for those who need >10 mg/day of prednisone. Low-dose aspirin reduces the incidence of ophthalmic complications in acute disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.

    Article  PubMed  Google Scholar 

  2. Schmidt WA. Takayasu and temporal arteritis. Front Neurol Neurosci. 2006;21:96–104.

    Article  PubMed  Google Scholar 

  3. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. European League Against Rheumatism – Ameican College of Rheumatology classification criteria for polymyalgia rheumatica. Ann Rheum Dis (in press).

    PubMed  Google Scholar 

  4. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8.

    Article  PubMed  CAS  Google Scholar 

  5. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287:92–101.

    Article  PubMed  Google Scholar 

  6. Schmidt WA, Gromnica-Ihle E. What is the best approach to diagnose large-vessel vasculitis? Best Pract Res Clin Rheumatol. 2005;19:223–42.

    Article  PubMed  Google Scholar 

  7. Schmidt WA. Current diagnosis and treatment of temporal arteritis. Curr Treat Options Cardiovasc Med. 2006;8:145–51.

    Article  PubMed  Google Scholar 

  8. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum. 2002;57:692–3.

    Google Scholar 

  9. Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology. 2007;46:672–7.

    Article  PubMed  CAS  Google Scholar 

  10. Cantini F, Salvarani C, Niccoli L, et al. Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J Rheumatol. 2004;31:120–4.

    PubMed  Google Scholar 

  11. Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol. 2005;23:462–8.

    PubMed  CAS  Google Scholar 

  12. Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis. 2008;67:758–61.

    Article  PubMed  CAS  Google Scholar 

  13. Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case–control study. J Rheumatol. 2001;28:1049–55.

    PubMed  CAS  Google Scholar 

  14. Frediani B, Falsetti P, Storri L. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J Rheumatol. 2002;29:123–30.

    PubMed  Google Scholar 

  15. Scheel AK, Schmidt WA, Hermann KG, et al. Interobserver reliability of rheumatologists performing musculoskeletal ultrasonography: results from a EULAR “train the trainers” course. Ann Rheum Dis. 2005;64:1043–9.

    Article  PubMed  CAS  Google Scholar 

  16. Bruyn GA, Naredo E, Möller I, et al. Reliability of ultrasonography in detecting shoulder disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;69:357–61.

    Article  Google Scholar 

  17. Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337:1336–42.

    Article  PubMed  CAS  Google Scholar 

  18. Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol. 2005;184:283–7.

    PubMed  Google Scholar 

  19. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Diagnostic performance of ultrasonography for giant-cell arteritis: a meta-analysis. Ann Intern Med. 2005;142:359–69.

    PubMed  Google Scholar 

  20. Schmidt WA, Gromnica-Ihle E. Duplex ultrasonography in temporal arteritis. Ann Intern Med. 2003;138:609.

    PubMed  Google Scholar 

  21. Bley TA, Uhl M, Carew J, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol. 2007;28:1722–7.

    Article  PubMed  CAS  Google Scholar 

  22. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol. 2005;17:9–15.

    Article  PubMed  Google Scholar 

  23. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203–11.

    Article  PubMed  Google Scholar 

  24. Schmidt WA, Wagner AD. Role of imaging in diagnosis of and differentiation between vasculitides. Fut Rheumatol. 2006;1:627–34.

    Article  Google Scholar 

  25. Schmidt WA. The role of color and power Doppler sonography in rheumatology. Nat Clin Pract Rheumatol. 2007;3:35–42.

    Article  PubMed  Google Scholar 

  26. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology. 2008;47:403–8.

    Article  PubMed  CAS  Google Scholar 

  27. Stanson AW. Imaging findings in extracranial (giant cell) temporal arteritis. Clin Exp Rheumatol. 2000;18(4 Suppl 20):S43–8.

    PubMed  CAS  Google Scholar 

  28. Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55:131–7.

    Article  PubMed  Google Scholar 

  29. Hautzel H, Sander O, Heinzel A, Schneider M, Müller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: Introducing an ROC-analysis-based cutoff ratio. J Nucl Med. 2008;49:1107–13.

    Article  PubMed  Google Scholar 

  30. Mahr A, Saba M, Kambouchner M, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65:826–8.

    Article  PubMed  CAS  Google Scholar 

  31. Sharma NS, Ooi JL, McGarity BH, Vollmer-Conna U, McCluskey P. The length of superficial temporal artery biopsies. ANZ J Surg. 2007;77:437–9.

    Article  PubMed  Google Scholar 

  32. Narváez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37:13–9.

    Article  PubMed  Google Scholar 

  33. Makkuni D, Bharadwaj A, Wolfe K, Payne S, Hutchings A, Dasgupta B. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology. 2008;47:488–90.

    Article  PubMed  CAS  Google Scholar 

  34. Chatelain D, Duhaut P, Schmidt J, et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis. 2009;68:84–8.

    Article  PubMed  CAS  Google Scholar 

  35. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–7.

    Article  PubMed  CAS  Google Scholar 

  36. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology. 2008;47:96–101.

    Article  PubMed  CAS  Google Scholar 

  37. Schmidt WA, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology. 2008;47:1406–8.

    Article  PubMed  CAS  Google Scholar 

  38. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122:502–7.

    PubMed  CAS  Google Scholar 

  39. García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum. 2008;59:422–30.

    Article  PubMed  Google Scholar 

  40. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988;47:733–9.

    Article  PubMed  CAS  Google Scholar 

  41. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–14.

    PubMed  CAS  Google Scholar 

  42. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–18.

    Article  PubMed  CAS  Google Scholar 

  43. Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized double-blind, placebo-controlled trial. Ann Intern Med. 2004;141:493–500.

    PubMed  CAS  Google Scholar 

  44. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–30.

    PubMed  Google Scholar 

  45. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007;146:631–9.

    PubMed  Google Scholar 

  46. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332–7.

    Article  PubMed  CAS  Google Scholar 

  47. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Center for Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, Berlin, 13125, Germany

    Wolfgang A. Schmidt

Authors
  1. Wolfgang A. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang A. Schmidt .

Editor information

Editors and Affiliations

  1. Sanford Health Systems, 32nd Ave S 2400, Fargo, 58103, North Dakota, USA

    Yuri Nakasato

  2. , Department of Internal Medicine, University of Michigan, Zina Pitcher Place 109, Ann Arbor, 48109, Michigan, USA

    Raymond L. Yung

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Schmidt, W.A. (2011). Polymyalgia Rheumatica and Giant Cell Arteritis in the Elderly. In: Nakasato, Y., Yung, R. (eds) Geriatric Rheumatology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5792-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5792-4_23

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-5791-7

  • Online ISBN: 978-1-4419-5792-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation